Fresenius Kabi Recalls One Lot of Tyenne (tocilizumab-aazg) for Glass Particles
A single lot of the tocilizumab biosimilar Tyenne 400 mg/20 mL injection is recalled to the user level after glass particulates were found during internal investigation.
A critical recall of Tyenne due to glass particles.
Glass particles in injectable drugs can cause serious adverse events like organ damage or embolism. Fresenius Kabi recalled Tyenne due to glass particle contamination. Immediate removal from inventory and return of affected lot is necessary. The Tyenne batch recall prevents serious health risks from glass contamination.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?
Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.